Ranoflip-500 ER Tablets

Ranoflip-500 ER Ranolazine 500 mg Sustained Release Tablets

Ranoflip-500 ER is a sustained release oral tablet formulation containing Ranolazine 500 mg. Ranolazine is an antianginal medicine indicated for the treatment of chronic angina.

Ranolazine is used to help manage chronic angina and may be prescribed as part of an overall treatment regimen for patients with persistent anginal symptoms. It can be used alongside other cardiovascular medicines as determined by the treating healthcare professional.

Composition

Ranolazine Sustained Release Tablets 500 mg

Therapeutic Class

Antianginal

Uses of Ranoflip-500 ER

Ranoflip-500 ER may be prescribed for:

• Treatment of chronic angina
• Management of recurrent anginal symptoms
• Symptomatic management of stable angina as directed by a healthcare professional
• Use as an add-on antianginal therapy when clinically appropriate

How Ranoflip-500 ER Works

Ranolazine has antianginal effects and works through mechanisms that are different from traditional medicines that primarily reduce heart rate or blood pressure. It helps improve the balance between myocardial oxygen supply and demand during episodes associated with chronic angina.

Key Product Features

• Ranolazine 500 mg
• Sustained release formulation
• Oral tablet dosage form
• Antianginal medicine
• Intended for chronic angina management
• 10 x 10 tablets packing

Product Information

Brand Name: Ranoflip-500 ER

Composition: Ranolazine Sustained Release Tablets 500 mg

Dosage Form: Sustained Release Tablets

Route of Administration: Oral

Therapeutic Class: Antianginal

Packing: 10 x 10 Tablets

Important Information

Ranoflip-500 ER is a prescription medicine and should be used under the supervision of a qualified healthcare professional.

It is intended for the management of chronic angina and is not a medicine for stopping an acute angina attack once it has started.

Patients should take the medicine exactly as prescribed and should not crush, break or chew sustained release tablets unless specifically instructed by the prescribing healthcare professional.

Ranolazine may interact with several medicines, including certain CYP3A inhibitors and inducers. Patients should inform their doctor about all prescription medicines, over-the-counter medicines and supplements they are taking.

Ranolazine can prolong the QT interval in some patients. It should be used with appropriate medical evaluation, particularly in patients with relevant cardiac conditions or medicines that may also affect the QT interval.

Patients with liver or kidney problems should inform their healthcare professional before starting treatment, as dosage or treatment considerations may differ.

Seek immediate medical attention for severe or unusual symptoms, including signs of a serious allergic reaction, fainting or significant changes in heart rhythm.

Dosage and Administration

The dosage and duration of treatment should be determined by the prescribing healthcare professional.

The commonly recommended starting dose for ranolazine extended-release tablets is 500 mg twice daily, with adjustment based on clinical response and prescribing guidance.

The tablet should be swallowed whole and should not be crushed, broken or chewed.

Do not self-medicate or change the prescribed dose without medical advice.

Storage

Store according to the storage conditions specified on the approved product label.

Keep the tablets in their original packaging.

Protect from excessive heat, moisture and direct light where applicable.

Keep out of reach of children.

Product Summary

Ranoflip-500 ER contains Ranolazine 500 mg in a sustained release tablet formulation. It is an antianginal medicine used for the treatment of chronic angina under medical supervision.